Bicycle Therapeutics (NASDAQ: BCYC) — Perfil da empresa, notícias e dados financeiros
Bicycle Therapeutics is a U.K. biopharmaceutical company innovating drug development for oncology using bicyclic peptide technology.
Bicycle Therapeutics
Bicycle Therapeutics (NASDAQ:BCYC) focuses on innovating biotherapeutics through its proprietary bicyclic peptide technology. The Cambridge, U.K.-based company strives to address unmet needs across oncology and other serious diseases with its novel approach. Bicycle's unique technology platform enables the rapid development of a new class of drugs, aiming to provide a combination of the precision of monoclonal antibodies with the pharmacological properties of small molecules. Its lead projects are geared towards creating transformative treatments for cancer and other severe diseases, highlighting a commitment to improving patient outcomes. The pursuit of groundbreaking discoveries in drug development is at the core of Bicycle's operations and objectives, emphasizing its dedication to advancing healthcare through innovation.
Resumo
Operações
Produtos e/ou serviços de Bicycle Therapeutics
- BT1718, a targeted toxin for tumors with high expression of Membrane Type 1 Matrix Metalloproteinase (MT1-MTP).
- BT5528, a second-generation Bicycle Toxin Conjugate targeting EphA2, a protein overexpressed in many solid tumors.
- BT8009, targeting Nectin-4, a protein associated with urothelial, lung, and pancreatic cancers, delivering a potent cytotoxin.
- BT7480, a novel Bicycle Tumor-Targeted Immune Cell Agonist (Bicycle TICA™) aimed at engaging immune cells specifically within the tumor microenvironment.
- Immuno-oncology partnerships focusing on using the Bicycle platform to develop novel immuno-oncology candidates.
- Research collaboration with Genentech to discover, develop, and commercialize novel Bicycle-based therapeutics for multiple targets.
equipe executiva do Bicycle Therapeutics
- Kevin LeeCEO & Executive Director
- Michael SkynnerChief Scientific Officer
- Alistair MilnesChief Corporate Development Officer
- Christian HeinisScientific Founder
- Travis ThompsonChief Financial Officer
- Jennifer PerryChief Operating Officer
- Stephanie YaoSenior Vice President of Investor Relations and Corporate Communications
- Zafar QadirChief Legal Officer & General Counsel
- Phil JeffreySenior VP of Pre-Clinical Development
- Michael Charles-Ferguson HannayChief Product & Supply Chain Officer
Principais indicadores financeiros
Resultados divulgados pela Bicycle Therapeutics, em USD.
- Cap. de mercado
- 264,6 mi
- Receita (TTM)
- 61,2 mi
- P/L
- —
- LPA (diluído, TTM)
- -2.8
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 72,6 mi | -247,7 mi | -219 mi | |
| 35,3 mi | -209,9 mi | -169 mi | |
| 27 mi | -189,9 mi | -180,7 mi | |
| 14,5 mi | -116,7 mi | -112,7 mi |